Antiarrhythmic drugs, such as lidocaine, quinidine, and procainamide, have been shown to be effective against postischemic reperfusion injury in isolated rat lungs. Rat lungs were perfused at a constant flow with Krebs-Henseilet buffer supplemented with 4% bovine serum albumin and ventilated with air containing 5% CO2. The lungs were subjected to ischemia by stopping perfusion and ventilation for 60 min followed by 30 min of reperfusion. Lung injury was determined by measuring the increase in wet-to-dry lung weight ratio, while pulmonary arterial pressure and peak airway pressure were calculated from the pre-and postischemic differences. Lidocaine, quinidine, and procainamide at doses of 5, 10, and 20 mg/kg body weight, respectively, were found to attenuate the postischemic lung injury significantly (p<0.0001). The formation of cyclooxygenase products, which were elevated during reperfusion, was also significantly (p<0.0001) inhibited by these drugs. Since these antiarrhythmic agents are found to be powerful scavengers of hydroxyl radicals and can prevent membrane lipid peroxidation, these findings suggest that the antioxidant properties of these drugs may, in part, be responsible for protecting the lungs against reperfusion injury. -Environ Health Perspect 102(Suppl 10): 117-122 (1994) 
Introduction
Lung transplant is rapidly becoming a clinical alternative for patients with end-stage lung disease. Preservation of the cadaver lung during transplant has been a major impediment to the wide clinical use of transplant procedures. Reperfusion of transplanted lung previously subjected to brief period of ischemia causes irreversible tissue injury (1) . Ischemia-reperfusion injury has been extensively studied in many organs, including brain, heart, intestine, and kidney (2) (3) (4) (5) (6) (7) . Little work has been done to elucidate the mechanism of reperfusion injury in the lung. Reactive oxygen species has been implicated in the etiology of ischemia-reperfusion injury (3, (8) (9) (10) . Antiarrhythmic drugs have been used as membrane stabilizers and were found to prevent microvascular permeability resulting from acute lung injury (11) . The mechanism by which these antiarrhythmic agents diminish lung edema, however, is unclear and their ability to reduce postischemic reperfusion injury of the lung has not been tested. Recently we reported that antiarrhythmic agents such as lidocaine, quinidine, and procainamide are potent hydroxyl radical scavengers and were found to inhibit lipid peroxidation (12) . Since free radicals of oxygen are important in initiating lipid peroxidation (13, 14) , and lipid peroxides are known to be produced during postischemic reperfusion of lung (15) , we developed the hypothesis that antiarrhythmic drugs may protect lungs from reperfusion injury. Here we present evidence that antiarrhythmic drugs such as lidocaine, quinidine, and procainamide attenuate postischemic reperfusion injury in isolated perfused rat lung and these drugs were effective in preventing the accumulation of cyclooxygenase products during reperfusion of ischemic lung. 
Materials and Methods

Inducion ofLung Ischemia
Isolated lungs were perfused for 10 min to ensure a stable preparation and were then subjected to ischemic injury for 60 min by stopping ventilation and perfusion. The lungs were inflated by instillating 2 ml of gas mixture into tracheal cannula before occlusion at the start of the ischemic period. Lung inflation was done to facilitate reperfusion after ischemia. Throughout the 60-min ischemia the lungs and perfusate were kept at 37°C.
Lung Reperfision
Reperfusion after ischemic interval was started slowly and the flow rate was increased such that a mean pulmonary Pa of 14 mm Hg was never exceeded. Within 5 min of the onset of the reperfusion the perfusate flow was increased to the original flow rate present before the ischemic period (0.05 ml/min/g, bw). During reperfusion the perfusate reservoir and the lungs were maintained at 37 to 38°C. Lungs were reperfused for 30 min while they were ventilated with the same gas mixture.
Experimental Groups
Five experimental groups were studied. The first group of six lungs underwent 60 min of ischemia followed by 30 min of reperfusion. The same protocol was maintained for groups 2, 3, and 4 (n = 6) with the exception that lidocaine, quinidine, and procainamide at 5, 10, and 20 mg/kg bw, respectively, were added to the perfusate. This dose was calculated taking the blood volume at 8% of the body weight. Group 5 served as control and underwent no ischemia. The drugs were added to the lung perfusate at the onset of lung perfusion prior to ischemia.
Measurement ofLung Injury
Wet-to-Dry Lung Weight Ratio. At the end of each experiment the left main stem bronchus was transected and the left lung was isolated for the determination of the wet-to-dry lung weight ratio. Lungs were weighed and placed in a convection oven (Model 605, Precision Scientific Inc., Chicago, IL) at 1200C and weighed daily for 3 days. Lung weight at 72 hr was reported as dry weight because no further weight loss occurred after that time.
Pulmonary Artery Pressure. Mean pulmonary Pa was measured for 10 min during the preischemic period and entire postischemic period after the full flow was resumed. Percentage change was calculated taking the difference of the mean pre-and postischemic pulmonary artery pressures.
Peak Airway Pressure. Mean peak Paw was monitored for 10 min of preischemic period and 30 min during postischemic period. Percentage change was calculated taking the difference of pre-and postischemic pressures.
Measurement ofCydooxygenase Metabolites
TxB2 and 6-keto-PGFia, the stable metabolites of TxA2 and prostacyclin, respectively, were measured as indicators of cyclooxygenase metabolite production. Samples (1.8 Figure 1 . Effects of antiarrhythmic drugs on wet-to-dry lung weight ratio of ischemic-reperfused rat lung. Wetto-dry lung weight ratios obtained after 100 min of lung perfusion in experiments exposed to ischemia reperfusion (I/R) and I/R with lidocaine, quinidine, and procainamide at doses of 5, 10 and 20 mg/kg bw, respectively (equivalent of 170, 320 and 900 pM, respectively, in the perfusate). Values are mean ± SE. *p<0.0001 compared with ischemia-reperfused lungs. ** p<0.0001 compared to the control. For each treatment group, n = 6. of 30 min of reperfusion as recorded by a MacLab-4 connected to a linear force transducer (data not shown). Wet-to-dry lung weight ratio, a measure of edema formation, was significantly higher (p< 0.000 1) in ischemia-reperfused lungs compared to uninjured controls ( Figure 1 ). The antiarrhythmic drugs lidocaine, quinidine, and procainamide at single doses of 5, 10, and 20 mg/kg bw, respectively, significantly (p < 0.000 1) reduced the wetto-dry weight ratios compared to ischemiareperfused lungs (Figure 1 ).
Effect on Pulmonary Pressure
Pulmonary Pa remained stable over the 100 min of perfusion in the control lungs not subjected to ischemia. Lungs subjected to 60 min of ischemia were allowed to reach a stable Pa 10 min after the onset of reperfusion. The Pa was found to be significantly higher (p< 0.008) 10 min after the onset of reperfusion compared to the pressures present in the same lung during preischemia or compared to the Pa measured in the time-matched control lungs (Figure 2 dine, and procainamide at 5, 10 and 20 mg/kg bw, respectively, significantly reduced the Pa respectively, of ischemiareperfused lungs compared to untreated reperfused lungs (Figure 2 ).
Effect on Peak Airway Pressure Peak Paw remained stable over the 100 min of perfusion in the uninjured control lungs. Lungs subjected to ischemia and reperfusion had a significantly higher (p< 0.000 1) Paw after 30 min of reperfusion. Lungs subjected to ischemia reperfusion but treated with lidocaine (5 mg/kg bw), quinidine (10 mg/kg bw), and procainamide (20 mg/kg bw) had significantly (p< 0.000 1) reduced Paw compared to the untreated ischemia-reperfused lungs. These data are presented in Figure 3 . Effect ofAntiarrhythmic Drugs on Cydooxygenase Product Formation Measurements of 6-keto-PGFia and TxB2 in lung effluents collected prior to ischemia and in the time-matched lung effluents from the uninjured control lungs showed Discussion A major source of damage in postischemic reperfusion injury is believed to be the generation of oxygen-free radicals and other toxic oxygen metabolites (9, 17, 18) . These radicals and metabolites have been implicated in postischemic reperfusion injury in the heart, kidney, intestine, brain, and other organs (14, (18) (19) (20) . Studies in the postischemic reperfusion injury of the lungs also implicate toxic oxygen metabolite as a source of damage (8, 17, 21, 22) . M-sec-1 for quinidine, lidocaine and procainmide, respectively) and inhibitors of lipid peroxidation (12) . Therefore, it is likely that these drugs protect pulmonary tissue against postischemic reperfusion injury by preventing lipid peroxide formation and/or scavenging -OH.
The concentration of three antiarrhythmic drugs in the perfusat were 40, 120, and 250 pg/ml for lidocaine, quinidine, and procainamide, respectively. However these drugs are also known to bind to plasma albumin, thereby reducing the availability of free drug for therapeutic action (26 (27) have also reported similar findings and concluded that cyclooxygenase products are not primarily responsible for lung damage. It has been shown that lidocaine is not an inhibitor of prostaglandin biosynthesis in vitro (28) , but rather increases the production of prostacyclin (29) . Our data demonstrate that all these antiarrhythmic drugs inhibit cyclooxygenase product formation. Since -OH are known to be responsible for the release of arachidonic acid from membrane phospholipids (30) , it is possible that these drugs may not inhibit prostaglandin formation per se but might inhibit the liberation of arachidonic acid from phospholipids by scavenging OH radicals.
Nevertheless, the lung damage imposed by ischemia reperfusion could be the concommitant actions of both toxic oxygen products (21) and cyclooxygenase metabolites (23) . We conclude that the inhibition of cyclooxygenase product formation and the attenuation of postischemic lung injury by these drugs may, in part, be due to the removal of toxic oxygen metabolites generated during the reperfusion of the lung.
